Education
About Us
Working with TipRanks
Follow Us
Glenmark Pharmaceuticals Limited (IN:GLENMARK)
:GLENMARK
Total Valuation
Glenmark Pharmaceuticals Limited has a market cap or net worth of ₹483.35B. The enterprise value is ₹490.87B.
Market Cap₹483.35B
Enterprise Value₹490.87B
Share Statistics
Glenmark Pharmaceuticals Limited has 282,200,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding282,200,800
Owned by Insiders―
Owned by Institutions0.05%
Financial Efficiency
Glenmark Pharmaceuticals Limited’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 11.77%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)11.77%
Return on Capital Employed (ROCE)0.19
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.82
Inventory Turnover2.60
Valuation Ratios
The current PE Ratio of Glenmark Pharmaceuticals Limited is 40.67. Glenmark Pharmaceuticals Limited’s PEG ratio is 0.07.
PE Ratio40.67
PS Ratio0.00
PB Ratio5.46
Price to Fair Value4.81
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio0.07
Income Statement
In the last 12 months, Glenmark Pharmaceuticals Limited had revenue of 131.46B and earned 10.47B in profits. Earnings per share was 37.11.
Revenue131.46B
Gross Profit54.60B
Operating Income18.65B
Pretax Income13.99B
Net Income10.47B
EBITDA20.92B
Earnings Per Share (EPS)37.11
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Glenmark Pharmaceuticals Limited pays an annual dividend of ₹2.5, resulting in a dividend yield of 0.14%
Dividend Per Share₹2.5
Dividend Yield0.14%
Payout Ratio5.28%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.91
52-Week Price Change35.52%
50-Day Moving Average1.50K
200-Day Moving Average1.54K
Relative Strength Index (RSI)71.69
Average Volume (3m)39.00K
Important Dates
Glenmark Pharmaceuticals Limited upcoming earnings date is Aug 8, 2025, During Market Hours (Confirmed).
Last Earnings DateMay 23, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend DateSep 13, 2024
Financial Position
Glenmark Pharmaceuticals Limited as a current ratio of 1.56, with Debt / Equity ratio of 27.94%
Current Ratio1.56
Quick Ratio1.05
Debt to Market Cap0.05
Net Debt to EBITDA0.38
Interest Coverage Ratio9.01
Taxes
In the past 12 months, Glenmark Pharmaceuticals Limited has paid 3.52B in taxes.
Income Tax3.52B
Effective Tax Rate0.25
Enterprise Valuation
Glenmark Pharmaceuticals Limited EV to EBITDA ratio is 20.73, with an EV/FCF ratio of -27.51.
EV to Sales3.30
EV to EBITDA20.73
EV to Free Cash Flow-27.51
EV to Operating Cash Flow-52.42
Balance Sheet
Glenmark Pharmaceuticals Limited has ₹17.68B in cash and marketable securities with ₹24.73B in debt, giving a net cash position of ₹7.05B billion.
Cash & Marketable Securities₹17.68B
Total Debt₹24.73B
Net Cash₹7.05B
Net Cash Per Share₹24.98
Tangible Book Value Per Share₹261.86
Margins
Gross margin is 54.38%, with operating margin of 14.19%, and net profit margin of 7.97%.
Gross Margin54.38%
Operating Margin14.19%
Pretax Margin10.64%
Net Profit Margin7.97%
EBITDA Margin15.92%
EBIT Margin12.22%
Analyst Forecast
The average price target for Glenmark Pharmaceuticals Limited is ₹1,785.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target₹1,785.00
Price Target Upside25.83% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―